Paulson & Co’s GSK GSK Stock Holding History

Paulson & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-231,600	Closed	-$12.5M	–	69
2017 Q2	$12.5M	Sell	231,600 -100,480	-30%	-$5.36M	0.17%	57
2017 Q1	$17.5M	Buy	332,080 +95,280	+40%	+$4.83M	0.23%	46
2016 Q4	$11.4M	Buy	+236,800	New	+$11.7M	0.14%	63

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Paulson & Co's GSK Position: Q3 2017 in Review

Paulson & Co sold out of GSK (GSK) in Q3 2017, closing a stake of 231,600 shares — an estimated $12.5M sold.

Paulson & Co first reported a position in GSK in Q4 2016 and held it in 3 quarters. The position peaked at $17.5M in Q1 2017. 741 funds tracked by Wall St. Rank hold GSK as of Q3 2017.

Paulson & Co reported no remaining GSK position as of Q3 2017 after selling out during the quarter.
Paulson & Co sold 231,600 GSK shares in Q3 2017, an estimated $12.5M.
Paulson & Co first reported a position in GSK in Q4 2016 and held it in 3 quarters.
Paulson & Co's GSK position peaked at $17.5M in Q1 2017.
741 funds tracked by Wall St. Rank held GSK as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.